Listed

PharmaCyte Biotech, Inc.: Form 10-Q for the period ended Jan 31, 2019

Filed with the SEC on Mar 14, 2019 and accepted by EDGAR at Mar 14, 2019, 17:21 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2019-01-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2018-11-01 to 2019-01-31$0us-gaap:Revenues
Revenue9 months2018-05-01 to 2019-01-31$0us-gaap:Revenues
Research and development3 months2018-11-01 to 2019-01-31$59.1kus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2018-05-01 to 2019-01-31$442.0kus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2018-11-01 to 2019-01-31−$676.3kus-gaap:OperatingIncomeLoss
Operating income9 months2018-05-01 to 2019-01-31−$2.9mus-gaap:OperatingIncomeLoss
Net income3 months2018-11-01 to 2019-01-31−$676.3kus-gaap:NetIncomeLoss
Net income9 months2018-05-01 to 2019-01-31−$2.9mus-gaap:NetIncomeLoss
Diluted EPS3 months2018-11-01 to 2019-01-31$0.00us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS9 months2018-05-01 to 2019-01-31$0.00us-gaap:EarningsPerShareBasicAndDiluted
Diluted shares (weighted)3 months2018-11-01 to 2019-01-311,126,904,505 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2018-05-01 to 2019-01-311,084,053,016 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2018-05-01 to 2019-01-31−$2.2mus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2019-01-31$699.5kus-gaap:Cash
Current assetsAt period end2019-01-31$707.9kus-gaap:AssetsCurrent
Total assetsAt period end2019-01-31$5.8mus-gaap:Assets
Current liabilitiesAt period end2019-01-31$471.2kus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2019-01-31$471.2kus-gaap:Liabilities
Shareholders' equityAt period end2019-01-31$5.4mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001683168-19-000666. Last ingested by Listed: Nov 14, 2026, 20:52 ET. Listed shows no prices and gives no investment advice.